

For Public Release  
NZX Limited  
Wellington

21 December 2023

### **Cannasouth Issues \$1,081,500 in Secured Convertible Notes**

Cannasouth Limited (NZX:CBD) launched a wholesale offer of secured convertible notes ("Notes") to raise up to \$5 million (See NZX announcement of 2 November 2023).

Today the Company announces the issue of a further \$1,081,500 of Notes. The Notes have been issued on the same terms as the earlier tranche of Notes issued, save for the fact that the new tranche of Notes has a maturity date of 24 months from the date of their issue. This brings the total amount of Notes issued to date to \$2,111,500. The new investors in the Notes are current CBD shareholders and wholesale investors (as that term is defined in the Financial Markets Conduct Act).

These Notes add to the capital received from the recent Rights Issue, which raised just under \$1.4 million. In the last two months, Cannasouth has now raised a total of circa \$3.45 million, which moneys are being applied towards funding Cannasouth's working capital requirements.

The Company is having discussions with other wholesale and eligible investors about participating in the Notes offer.

Wholesale and eligible investors wanting to participate in the Note offer should contact the Company.

-ENDS-

For further information visit [www.cannasouth.co.nz](http://www.cannasouth.co.nz) or contact:

**Mark Lucas**

CEO / Executive Director  
Email: [mark.lucas@cannasouth.co.nz](mailto:mark.lucas@cannasouth.co.nz)  
Mobile: 021 484 649

**Colin Foster**

CFO / Company Secretary  
Email: [colin.foster@cannasouth.co.nz](mailto:colin.foster@cannasouth.co.nz)  
Mobile: 027 577 1498

### **About Cannasouth Limited**

Cannasouth is a vertically integrated biopharmaceutical Group. The Group has been established to focus on the commercial development of the medicinally beneficial attributes of cannabinoid compounds produced by the cannabis plant, and other health products and medicines. Our goal is to support patients' health outcomes and improve their quality of life. Our products are produced under GMP, using environmentally friendly methods, ensuring patients are treated with therapeutic products of the highest quality. Cannasouth Limited is the parent company, listed on the NZX, and is 100% owner of Cannasouth Bioscience Ltd, Cannasouth Cultivation Ltd and Equalis Group New Zealand Ltd.

For video footage, photos and logos please visit: <https://www.cannasouth.co.nz/about/media/>